Clinical Trial Update: A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the immune response and safety of an adjuvanted human papillomavirus vaccine in healthy women aged 16 to 26; results were posted on 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia

Drugs mentioned

• Adjuvanted HPV vaccine (adjuvanted human papillomavirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cervical Intraepithelial Neoplasia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-02-03